Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620150 · ClinicalTrials.gov registry record · Phase 4
SSRI Effects on Depression and Immunity in HIV/AIDS
A Phase 4 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT02620150: Completed Phase 4 study, sponsored by University of Pennsylvania.
NCT02620150 is a Phase 4 study that has completed, run by University of Pennsylvania. The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620150, a Phase 4 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on innate immunity and inflammation. Depressed population is HIV + on cART (Combination Antiretroviral Therapy), not currently on pharmacotherapy for depression. Subjects will complete computerized cognitive behavior therapy, CCBT for their depression. Blood samples collected for virologic, neuroendocrine, and immunologic evaluation. Our overarching hypothesis is that SSRI treatment of depression and improvement of depressive symptoms leads to increased innate immunity and decreased inflammation, resulting in better control of HIV disease and decreased morbidity.
Interventions
- OTHER Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620150
The ClinicalTrials.gov registry entry for NCT02620150 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02620150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02620150 about?
NCT02620150 is a clinical study titled "SSRI Effects on Depression and Immunity in HIV/AIDS". This is a 10 week, double-blind, placebo controlled trial to evaluate SSRI (Selective Serotonin Reuptake Inhibitor) effects for treatment of depression in HIV/AIDS with a focus on innate immunity and inflammation. Depressed population is HIV + on cART (Combination Antiretroviral Therapy), not curren...
What is the current status of trial NCT02620150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2017-02-16. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT02620150?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT02620150?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.